SCHEMBL5067456

SCHEMBL5067456

CNCCN1CCC(c2ccc(NC(=O)c3ccccc3OC)c(C)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 7/20 0.53
MAPT P10636 2/20 0.52
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
CARM1 Q86X55 6/20 0.51
TLR7 Q9NYK1 3/20 0.49
BRPF1 P55201 2/20 0.49
PRMT6 Q96LA8 1/20 0.47
TLR4 O00206 1/20 0.47
TLR3 O15455 1/20 0.47
TLR8 Q9NR97 1/20 0.47
ALDH1A1 P00352 2/20 0.46
BRD4 O60885 1/20 0.46
CCR5 P51681 1/20 0.46
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
GAA P10253 2/20 0.45
TP53 P04637 1/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5069648 0.90 TLR9 (0.50) TLR9CARM1TLR7BRPF1PRMT6
SCHEMBL5066953 0.88 TLR9 (0.49) TLR9CARM1TLR7BRPF1PRMT6
SCHEMBL5066966 0.85 CARM1 (0.55) TLR9MAPTRAB9ANPC1CARM1
SCHEMBL4555575 0.85 KCNK3 (0.55) TLR9MAPTCARM1TLR7PRMT6
SCHEMBL14012686 0.82 MAPT (0.45) MAPTRAB9ANPC1BRPF1ALDH1A1
SCHEMBL5070546 0.73 CARM1 (0.57) TLR9CARM1TLR7PRMT6ALDH1A1
SCHEMBL18764021 0.70 EGFR (0.49) TLR9TLR7TLR4TLR3TLR8
SCHEMBL4734309 0.70 FASN (0.58) MAPTRAB9AALDH1A1
SCHEMBL4563395 0.70 DRD3 (0.46) BRPF1ALDH1A1BRD4DRD2DRD4
SCHEMBL21701459 0.69 RXFP1 (0.54) MAPTRAB9ANPC1BRPF1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280925-A1 Amines as Small Molecule Inhibitors CARM1, PRMT1, PRMT3 TLR9 4495/4885MAPT 71/4885RAB9A 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.